Union européenne - slovaque - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - iressa je indikovaný na liečbu dospelých pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer s aktiváciou mutácie pokožky-rastový faktor-receptor tyrozín kinase.

Union européenne - slovaque - EMA (European Medicines Agency)

actavis group ptc ehf - topotekan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastické činidlá - monoterapia topotekánom je indikovaná na liečbu pacientov s relapsovaným malobunkovým karcinómom pľúc [sclc], u ktorých sa opakované liečenie s režimom prvej línie nepovažuje za vhodné. topotecan v kombinácii s cisplatin je indikovaný u pacientov s karcinóm krčka maternice opakujúce sa po rádioterapii a pre pacientov s Štádium ivb ochorenia. pacienti s predchádzajúcim expozície cisplatin vyžadujú trvalé ošetrenie zdarma interval na odôvodnenie liečby v kombinácii.

Slovaquie - slovaque - Ecolab

ecolab deutschland gmbh -

Union européenne - slovaque - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Union européenne - slovaque - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotické činidlá - duoplavin je indikovaný na sekundárnu prevenciu aterotrombotických príhod u dospelých pacientov, ktorí už užívajú klopidogrel a kyselinu acetylsalicylovú (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. Ďalšie informácie nájdete v časti 5.

Union européenne - slovaque - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - sekundárnu prevenciu atherothrombotic eventsclopidogrel je uvedená v:u dospelých pacientov, ktorí trpia infarktu myokardu (od niekoľkých dní až menej ako 35 dní), ischaemic zdvih (od 7 dní do menej ako 6 mesiacov) alebo zriadené periférneho arteriálneho ochorenia. u dospelých pacientov, ktorí trpia akútneho koronárneho syndrómu:non-st segment elevation akútneho koronárneho syndrómu (nestabilná angína pectoris alebo non-q-vlna, infarkt myokardu), vrátane pacientov podstupujúcich stent umiestnenie týchto perkutánnej koronárnej intervencii, v kombinácii s acetylsalicylová (asa). st segment elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prevencia atherothrombotic a thromboembolic udalosti v fibrilácia fibrillationin dospelých pacientov s fibrilácia predsiení, ktorí majú aspoň jeden rizikový faktor cievnych udalosti, nie sú vhodné na liečbu s antagonisty vitamínu k (vka) a ktorí majú nízke riziko krvácania, klopidogrel, je indikovaná v kombinácii s asa pre prevenciu atherothrombotic a thromboembolic udalosti, vrátane mŕtvica.

Union européenne - slovaque - EMA (European Medicines Agency)

sanofi winthrop industrie - klopidogrel hydrogénsulfát - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prevencia atherothrombotic a thromboembolic udalosti v fibrilácia fibrillationin dospelých pacientov s fibrilácia predsiení, ktorí majú aspoň jeden rizikový faktor cievnych udalosti, nie sú vhodné na liečbu s vitamínom-k antagonisty a ktorí majú nízke riziko krvácania, klopidogrel, je indikovaná v kombinácii s asa pre prevenciu atherothrombotic a thromboembolic udalosti, vrátane mŕtvica.

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boiron, francúzsko - iné liečivá - 93 - homeopatica

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boiron, francúzsko - iné liečivá - 93 - homeopatica

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boiron, francúzsko - iné liečivá - 93 - homeopatica